Healthy Controls
Conditions
Brief summary
The purpose of this study is to understand the reliability of \[18F\]-FTC-146 brain uptake in healthy controls.
Detailed description
The purpose of this study is to understand the reliability of \[18F\]-FTC-146 brain uptake in healthy controls under test and retest conditions.
Interventions
DRUG[18F]-FTC-146
Two 5 mCi \[18F\]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
Sponsors
Stanford University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. ages 18-65 2. either gender and all ethno-racial categories 3. capacity to provide informed consent 4. Female participants are expected to use an effective method of birth control throughout the study
Exclusion criteria
1. Any current or lifetime psychiatric diagnosis 2. Current or past use of psychotropic medication 3. Pregnant or nursing females 4. Major medical or neurological problem 5. Presence of metal in the body that is contraindicated for MRI scans
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reliability under test retest conditions | 1 week | Regional brain uptake of \[18F\]FTC-146 will be analyzed by kinetic modeling with metabolite-corrected arterial input functions to establish stability and reproducibility of \[18F\] FTC-146 VT in humans (n=6) under test and retest conditions. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORCarolyn Rodriguez, MD, PhD
Stanford University
Outcome results
None listed